Drug Profile
M 0004
Alternative Names: M0004Latest Information Update: 16 Jan 2019
Price :
$50
*
At a glance
- Originator Janssen Pharmaceutica; Ortho-McNeil Pharmaceutical
- Developer Shire-Movetis NV
- Class Gastrokinetics
- Mechanism of Action Serotonin 4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gastro-oesophageal reflux
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 04 Nov 2017 No recent reports of development identified for phase-I development in Gastro-oesophageal-reflux(In children) in Europe
- 03 Aug 2010 Shire proposes to acquire Movetis